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INTRODUCTION
Increased glucose uptake and aerobic glycolysis are characteristics of transformed cells that have been exploited in the development of cancer therapeutics Warburg et al., 1927) . Not generally appreciated, however, is the fact that glucose levels are usually extremely low (<1 mM) within solid tumors (Hirayama et al., 2009; Ho et al., 2015; Urasaki et al., 2012) . This implies that solid tumors are likely to be in a constant state of metabolic stress, and they must have the ability to adapt to alterations in glucose availability. Interestingly, intratumoral levels of lactate (5-10 mM) are much higher than glucose in many different tumor types (Kennedy et al., 2013; Schroeder et al., 2005; Walenta et al., 2003) . The potential significance of this observation has been highlighted in recent studies which demonstrated that lactate produced by glycolytic cells within the hypoxic regions of tumors, or by cancer associated fibroblasts, can be taken up by cells in more oxygenated regions of the tumor where it is further oxidized to produce ATP (Boidot et al., 2012; Pavlides et al., 2009; Sonveaux et al., 2008) . These findings, as well as the results of additional studies, have highlighted the importance of functional mitochondria in cancer pathogenesis (Viale et al., 2015) .
Under glucose replete conditions, most cancer cells are glycolytic and increases in the demand for ATP production can be met by enhancing glycolytic flux (Pfeiffer et al., 2001) . However, the observations that glucose is generally limiting within tumors and that oxygen tension is both spatially and temporally dynamic suggests that the ability to engage mitochondria for energy production in tumors are also likely to be important. Indeed, accumulating evidence suggests that cancer cells utilize both glycolysis and mitochondrial oxidative metabolism to satisfy their metabolic demands (Koppenol et al., 2011; Zu and Guppy, 2004 ). This conclusion would appear to be at odds with the observation that most cells within tumors are in regions of hypoxia where oxygen-dependent oxidative phosphorylation (OXPHOS) was assumed to be inactive. However, it has been shown that mitochondrial oxidative phosphorylation is active within cells located in environments with oxygen levels as low as 0.5% (Chandel et al., 1996; Rumsey et al., 1990; Weinberg and Chandel, 2015) . This suggests that even within hypoxic regions of tumors complete oxidation of glucose (and lactate) are not only possible, but also are likely to be important for tumor cell viability.
The observation that mitochondria play a key role in tumorigenesis has driven efforts to identify cancer chemotherapeutics that function by targeting oxidative metabolism (Weinberg and Chandel, 2015) . Notable is the interest in the potential anticancer activities of metformin, a widely prescribed antidiabetic drug that can inhibit complex I within the mitochondrial electron transport chain (ETC) (Dowling et al., 2011; Foretz et al., 2014) . Notwithstanding the potential utility of metformin in cancer, there is a need for additional therapeutics that interfere with mitochondrial function in a manner that minimizes the impact on normal cells. The estrogen-related receptor alpha (ERRa), a druggable transcription factor that regulates mitochondrial biogenesis and function, is thus a potentially useful therapeutic target.
ERRa is expressed in most cancers and increased activity of this receptor is associated with a negative outcome in breast and ovarian cancers (Chang et al., 2011; Fujimoto et al., 2007; Lam et al., 2014; Suzuki et al., 2004) . This transcription factor has been shown to be involved in mitochondrial biogenesis and in the regulation of OXPHOS (Chang et al., 2011; CharestMarcotte et al., 2010; Huss et al., 2007) . Given the restricted nature of its expression, and the subtle phenotypes in animals in which this receptor is ablated, we considered that inhibition of its activity would enable a selective disruption of mitochondrial function in cancer. In this study, it is demonstrated that the ability of breast cancer cells to oxidize lactate is essential for viability under conditions of glucose deprivation, and that disruption of mitochondrial function using ERRa antagonists inhibits lactate utilization. It was further demonstrated that most breast cancer cells that actively engage OXPHOS are insensitive to the inhibitory effects of PI3K/mTOR inhibitors, but that the efficacy of these targeted therapies can be enhanced by coadministration of an ERRa antagonist. The clinical utility of PI3K inhibitors has been restricted by their dose limiting toxicities (Bendell et al., 2015; Burris et al., 2010) . Thus, it was significant that we could show in vivo that the effective dose of select PI3K inhibitors could be reduced using drug regimens that included an ERRa antagonist.
RESULTS

Evaluation of the Impact of Lactate Metabolism on Processes of Pathological Importance in Cellular Models of Breast Cancer
There is a high level of interest in defining metabolic vulnerabilities in cancers that can be exploited in the development of new therapeutics. Much of this effort has focused on developing strategies to effect a useful inhibition of glycolysis, although the recent definition of essential roles for mitochondrial function in cancer pathogenesis has highlighted new opportunities for intervention. Notable is the observation that although cancer cells are avid consumers of glucose, intratumoral levels of glucose are usually exceedingly low (Hirayama et al., 2009) . Under these circumstances of low glucose, tumor cells can take up and oxidize lactate (Sonveaux et al., 2008) . However, the role(s) that lactate plays in cancer pathogenesis, its metabolic fate, the pathways that regulate its utilization, and the impact of manipulating those pathways remain important issues to be addressed.
Considering the paucity of therapeutics available for patients with triple negative breast cancer (TNBC), we first explored lactate biology in cellular models of this disease. In preliminary studies it was observed that when grown in different concentrations of glucose, MDA-MB-436 (MDA436) cells (a model of TNBC) produced lactate, but switched from net lactate producers to consumers when glucose was limiting ( Figure S1A ). The importance of this observation was evaluated by growing MDA436 cells in the presence of different concentrations of glucose in the absence or presence of 10 mM sodium lactate and assessing cell growth/viability. As shown in Figure 1A , cell viability was unaffected by lactate in high glucose conditions (12.5 mM; standard media conditions). Viability was compromised, however, when cells were grown in lower glucose concentrations, but this was mitigated by supplementation with lactate or methyl pyruvate (MP; a mitochondrial permeable form of pyruvate) (Figures 1A and S1B) . Using the same experimental paradigm, it was demonstrated that lactate was similarly protective in a large number of cell lines that model different subtypes of breast cancer ( Figures 1B and S1C ). Annexin V staining of lactate (or MP) treated cells confirms that the protection of cell viability observed can be attributed to reduced apoptosis ( Figures 1C and S1D ). Not unexpectedly, cellular ATP levels were maintained by lactate supplementation when glucose was withdrawn from cells ( Figure 1D ). The potential biological significance of these findings was revealed in studies where cells were maintained in the absence or presence of lactate for 6 days (without media change), at which time they were supplemented with glucose. As shown in Figures 1E and S1E , those cells that were maintained in lactate (or MP) were able to proliferate upon glucose refeeding, suggesting that lactate serves to maintain cell viability until glucose becomes available.
Lactate Serves as a Respiratory Substrate in Cancer Cells when Glucose Is Limiting Whereas we and others have shown that lactate can serve as a fuel source when glucose is limiting, there remains disagreement in the field as to whether it enters the tricarboxylic acid (TCA) cycle directly or if it must first be converted to glucose through gluconeogenesis (Leithner et al., 2015) . Whereas some cancer cells do have the ability to support gluconeogenesis (Chen et al., 2015; Leithner et al., 2015) , we demonstrated that the protective effect of lactate (and MP) in MDA436 cells was unaffected by small interfering (si)RNA-mediated knock down of pyruvate carboxylase, the first anaplerotic enzyme in the gluconeogenic pathway (Figures 2A and S2A ). This suggested that pyruvate was serving as a catabolic substrate in glucose deprived cells, and that it relied on the activity of the pyruvate dehydrogenase (PDH) complex to enter the TCA cycle. We demonstrated that the PDH complex is active in low glucose conditions (hypophosphorylation at serine 293 of the E1 alpha subunit of the PDH complex), and that it remains active upon the addition of lactate or MP ( Figure 2B ). It was also shown that the protective effect of lactate on cell viability required PDH activity (Figures 2C and S2B) .
Demonstration that 14 C-labeled CO 2 is released from MDA436 cells that were incubated with [U-
14 C]-lactate confirms that lactate can enter the TCA cycle ( Figure 2D ). Further, a previously published survey of [3-
13
C]-lactate metabolism in vitro and in vivo using nuclear magnetic resonance also indicated that lactate can be transported into and oxidized in cancer cells (Gallagher et al., 2009; Kennedy et al., 2013) . Although confirming that lactate can be utilized, these studies do not provide a quantitative assessment of lactate entry into the TCA cycle, information that would help to evaluate its importance as a respiratory substrate. Thus, we undertook a comprehensive isotopomer analysis using [U-
13 C]-labeled lactate in MDA436 and HCC1937 cells. In MDA436 cells, it was determined that (1) under conditions of glucose deprivation, over 50% of the total cellular pool of TCA cycle intermediates were derived from lactate; (2) alanine, glutamate, and aspartate, amino acids generated from pyruvate or from other TCA cycle intermediates (E) MDA436 cells were cultured in glucose-free media supplemented with or without 10 mM sodium lactate for 6 days and vehicle (Veh; media) or glucose (Glc; final 12.5 mM) was added back to culture media at day 6 and harvested on days as indicated. The cell number was determined by staining Hoechst 33258.
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were also heavily enriched with the 13 C label; (3) significant labeling of phosphoenolpyruvate (PEP) was observed although fructose 1,6-bisphosphate (FBP), hexose-phosphate (G6P), and glucose (Glc) were almost undetectable; (4) pyrimidines (UTP and CTP), derived from aspartate, were also labeled with 13 C, but no labeling of purines was detected; and (5) only low amounts of the 13 C label were incorporated into fatty acids (Figure 2E) . Similar results were observed in HCC1937 cells (Figure S2C) . Together, these data suggest that in the absence of glucose, lactate contributes significantly to the TCA cycle and anaplerosis, but does not undergo gluconeogenesis in these model systems.
One question that arises from the results of the studies above is how cancer cells regenerate the NAD + needed to enable the sustained production of pyruvate from lactate. It was significant, therefore, that we determined that the protective effect of lactate in MDA436 cells was reduced by siRNA-mediated knock down of malate dehydrogenase (MDH1), suggesting that the malateaspartate shuttle was likely to play a significant role in regenerating the cytosolic NAD + needed for lactate oxidation ( Figure 2F ).
Lactate Utilization Requires Glutamine to Attenuate Reactive Oxygen Species Production
The production of mitochondrial reactive oxygen species (ROS) is a significant liability of oxidative metabolism in that it can lead to mitochondrial damage, genome instability, and contribute to resistance to chemotherapeutics (Liou and Storz, 2010 glutamine), a likely consequence of the oxidation of endogenous respiratory substrates. Not unexpectedly, ROS was low under the same conditions when cells were supplemented with 12.5 mM glucose. Surprisingly, using the same experimental paradigm (RPMI containing 2 mM glutamine), lactate was as effective as glucose in suppressing basal ROS production ( Figure 3A , left). A potential explanation for this observation came from the isotopomer experiments, where it was determined that the reduced glutathione (GSH) pool was derived from both 13 C-lactate and 13 C-glutamine in glucose free conditions, raising the possibility that together, lactate and glutamine present in the media, are sufficient to overcome ROS production associated with lactate oxidation (Figures S3A and S3B ). To address this possibility, we repeated the studies in glutamine free media ( Figure 3A, center) . The informative results of this experiment indicated that whereas glucose alone was capable of suppressing ROS production, lactate, absent glutamine, was unable to achieve the same result. The observation that the addition of GSH obviated the need for glutamine suggests that one of its roles in lactate fueled cells is to contribute reducing equivalents to attenuate ROS production ( Figure 3A, right) . Thus, whereas glutamine is important for anapleurosis and can contribute to cell biomass in proliferating cells through oxidative and reductive carboxylation, it appears that it also plays an essential role in lactate support of cell viability in low glucose conditions. This hypothesis was confirmed in lactate complementation studies where it was demonstrated that the ability of lactate to support cell viability ( Figure 3B ) and prevent apoptosis ( Figure S3C ) in the absence of glucose required glutamine or Figure 4B and whole-cell extracts were analyzed by immunoblotting to determine the expression of PGC-1a and ERRa. b-actin was used as a loading control. (D) MDA436 cells were transfected with either control (siCtrl) or ERRa (siERRa-A and siERRa-B) siRNAs for 24 hr, followed by infection of adenoviruses expressing b-gal (negative control), wild-type PGC-1a, ERRa selective PGC-1a (2X9), or the nuclear receptor-binding deficient PGC-1a (L2L3M) for 48 hr. The qRT-PCR data were normalized to expression of 36B4. The heatmaps were derived from qRT-PCR data using R software.
(legend continued on next page) GSH supplementation. It was also demonstrated that removal of glutamine did not decrease lactate oxidation as measured by 14 CO 2 release from 14 C-lactate, ruling out the possibility that the failure of lactate alone to rescue cell viability in these assays is a result of the inability of cells to oxidize lactate in the absence of glutamine ( Figure 3C ). Indeed, it was observed that the oxidation of lactate was actually increased when glutamine was absent, a possible consequence of an increase in the amount of lactate that was committed to oxidative metabolism by the TCA cycle/OXPHOS to compensate for the reduced flux of glutamine into this pathway. Similarly, the oxidation of glutamine was increased in cells in the absence of lactate (data not shown).
Inhibition of ERRa Attenuates Mitochondrial Oxidation of Lactate
The ability of breast cancer cells to utilize lactate as a metabolic substrate highlights the potential therapeutic utility of selectively targeting mitochondrial metabolism. This, we hypothesized, could be accomplished by inhibiting the activity of the ERRa, an orphan nuclear receptor that is expressed in most cancers that has been shown to play a key role in mitochondrial biogenesis and function (Gaillard et al., 2006) . With respect to lactate metabolism, it was significant that a reanalysis of the ERRa transcriptome, reported previously (Chang et al., 2011) , revealed that the expression of the mRNAs encoding the monocarboxylate transporter 1 (MCT1), lactate dehydrogenase B (LDHB), and proteins involved in both the TCA cycle and OXPHOS were positively regulated by this receptor ( Figure 4A , highlighted in red). Thus, the impact of modulating ERRa activity on the expression of genes involved in glycolysis, the TCA cycle, OXPHOS, and pyruvate metabolism in multiple breast cancer cell lines was undertaken. Small molecule agonists for ERRa have not yet been identified, making it difficult to manipulate the activity of this receptor. However, we have previously demonstrated that this limitation can be circumvented by expressing one of the obligate ERRa coregulators (PGC1a or PGC1b) in target cells (Chang et al., 2011; Gaillard et al., 2006) . As PGC1a/b can also serve as coregulators for many other transcription factors, the specific role of ERRa as a mediator of the PGC-1a/b induced changes was confirmed using PGC-1a (or PGC-1b) mutants that (1) were engineered to be highly selective for ERRa (2X9) or (2) were unable to interact with any nuclear receptors (L2L3M) (Gaillard et al., 2006) . Using these previously validated tools, it was demonstrated that PGC1a/ERRa upregulated the expression of most of the genes involved in the TCA cycle, OXPHOS, and lactate metabolism in MDA436 cells (Figures 4B and 4C ) and in MDA231 and SKBR3 cells ( Figure S4A ). Two different siRNAs directed against ERRa were used to demonstrate that this receptor was required for the expression of the implicated genes in MDA436 cells ( Figures  4D and 4E ) and in MDA231 cells ( Figure S4B ). Not surprisingly, siRNA-mediated knock down of ERRa decreased oxygen consumption ( Figure S4D ) and prevented lactate support of cell viability in low glucose conditions ( Figures 4F and S4C ). Considering the results of several studies indicating that a significant amount of ATP generated in cancer cells is derived from mitochondrial oxidative metabolism, it was a surprise that ERRa knockdown had no significant effect on cell viability in glucose replete conditions (Figures 4F and S4C) . However, it was observed that the decrease in oxygen consumption rate (OCR) observed upon ERRa knockdown was accompanied by an increase in the extracellular acidification rate (ECAR), indicative of increased lactate secretion ( Figures S4E and S4F ). This increase in extracellular lactate was likely due to increased glycolysis as treatment of cells with an ERRa antagonist resulted in increased glucose consumption and an increase in lactate production in high glucose media ( Figure S4G ). Taken together, the results of these experiments highlight the direct role of ERRa in glucose/lactate oxidation and how decreased mitochondrial function can be compensated for by increased glycolysis.
Inhibition of Mitochondrial Metabolism Using ERRa Antagonists as a Therapeutic Approach in Cancer
The impact of two chemically and mechanistically distinct small molecule inhibitors of ERRa (compound 29 [Cpd29] and XCT790) on lactate-mediated rescue of glucose-deprivation induced cell death was assessed. These studies revealed that both Cpd29 (Patch et al., 2011) and XCT790 (Willy et al., 2004) inhibited the ability of lactate (or MP) to support cell viability in no/low glucose conditions ( Figures 5A and S5A-S5C ) and attenuated lactate oxidation ( Figure 5B ). It was also observed that the expression of those genes required for lactate metabolism was also reduced by ERRa inhibition ( Figure 5C ). As indicated above, ERRa likely inhibits several processes that are involved in cancer pathogenesis, but it is important to note that treatment with Cpd29 significantly reduced the flux of lactate into the TCA cycle as evidenced by a decrease in the enrichment of 13 C-labeled lactate into TCA cycle intermediates ( Figures 5D and 5E ). Decreased flux of lactate into alanine, glutamate, and aspartate was observed in the Cpd29 treated cells. Interestingly, lactate flux into PEP, serine, and glycine were significantly increased in the presence of Cpd29 ( Figure S5D ), a result that is consistent with an increase in 13 C-labeled pyruvate derived from 13 C-lactate ( Figure S5E) . One of the most important effects of ERRa antagonism noted in our untargeted metabolite analysis was the reduction in the pool size of both GSH and the GSH precursor (g-L-glutamyl-Lcysteine) in Cpd29 treated cells ( Figure S5F ). Although lactate only contributes to about 15% of the total pool of GSH, it was important to note that the flux of 13 C lactate into GSH/GSSH was decreased upon ERRa inhibition ( Figure S5G ). These data suggest that in addition to inhibiting lactate oxidation, the cytotoxic activity of Cpd29 in low/no glucose conditions may also be attributable to its ability to interfere with the ability of cells to handle oxidative (ROS) stress.
Whereas there is strong rationale for developing ERRa antagonists for cancer, we also wanted to explore additional pharmaceutical approaches that could be used to attenuate the protective activity of lactate in cancer cells. Recently, metformin and other biguanides, which disrupt mitochondrial function, have received considerable attention as potential cancer chemotherapeutics (Foretz et al., 2014) . Thus, the ability of metformin to impact lactate dependent support of cell viability in low/ no glucose conditions was assessed. The results of this study in MDA436 breast cancer cells indicate that high concentration of metformin (1 mM), but not lower dose (50 mM), was effective in this assay, consistent with the findings of others who have reported a similar efficacy for this drug in cell viability assays ( Figure S5H ). Although in very early development the potential utility of the mitochondrial pyruvate carrier (MPC) inhibitor (Schell et al., 2014) , UK5099, was also evaluated and was shown to inhibit lactate mediated cell survival in vitro ( Figure S5I ). Thus, while metformin and UK5099 have desirable activities, the efficacy and elevated expression of ERRa in cancer make antagonists of this receptor attractive for clinical development as cancer therapeutics.
Cells Using Lactate as a Metabolic Substrate Are Resistant to PI3K/mTOR Inhibitors
The anticancer efficacy of PI3K/mTOR inhibitors has been attributed in part to their ability to inhibit glucose uptake and/or metabolism . Thus, given the ability of cancer cells to switch between glycolytic and mitochondrial oxidative metabolism, the efficacy of selected inhibitors as a function of the metabolic status of cells was assessed. It was noted that breast cancer cell growth in high glucose media (12.5 mM) could be inhibited by BEZ235, GDC0980 (dual PI3K/ mTOR inhibitors), or LY294002 and GDC0941 (PI3K inhibitors). However, when lactate was used as the primary metabolic substrate, MDA436 cells were completely resistant to these inhibitors ( Figures 6A and S6A) . A similar impact of lactate on sensitivity to BEZ235 was observed in other breast cancer cell lines evaluated under the same conditions ( Figure S6B ). The very reproducible increase in cell number observed in PI3K/ mTOR inhibitors treated cells in the presence of lactate can be attributed to increased lactate dependent activation of mitogen-activated protein kinase (MAPK) and to the disruption of the inhibitory feedback of AKT on MAPK upon the addition of PI3K/mTOR inhibitors (unpublished data). Lactate oxidation was not influenced by the treatment of cells with the selected PI3K/mTOR inhibitors, suggesting that by utilizing lactate, cancer cells can bypass the need for glycolysis and are thus less sensitive to PI3K/mTOR inhibitors ( Figure 6B ). It is thus inferred that ERRa antagonists would block the adaptive responses that enable cells to escape PI3K/mTOR inhibition. As shown, the resistance to BEZ235 or LY294002 observed in breast cancer cells utilizing lactate ( Figures 6C and 6D) or MP ( Figure S6C ) could be attenuated by coaddition of the ERRa antagonist Cpd29. Similar results were found when GDC0980 and GDC0941 were evaluated under the same conditions (Figures S6D and S6E ) and when using a second ERRa antagonist, XCT790 ( Figures S6F-S6I ). To confirm that it was the disruption of mitochondrial function and not another component of ERRa biology that was responsible for the killing of cells resistant to PI3K/mTOR inhibitors, we demonstrated that metformin and UK5099, at concentrations that blocked lactate utilization, functioned in a similar manner as ERRa antagonists (Figures S6J-S6L) . Extension of these studies revealed that most cells that exhibited a luminal breast cancer phenotype and which expressed PIK3CA mutant (i.e., MCF-7 cells) were exquisitely sensitive to both PI3K/mTOR inhibitors and ERRa antagonists under all conditions examined ( Figures S6M and S6N) . However, as with the MDA436 cell model, we observed a similar resistance to PI3K/mTOR inhibitors in other cell models of TNBC when propagated in lactate, and that this resistance could be abrogated by cotreatment with Cpd29 ( Figures S6O and S6P) . It is not clear as yet why the ability to utilize lactate confers upon some cells, but not others, resistance to PI3K/mTOR inhibitors. However, these studies do highlight the potential clinical utility of combining ERRa antagonists with a PI3K/mTOR inhibitor in treatments for TNBC and other cancers that are PI3Kwt. Figure 6C were treated with ERRa antagonist Cpd29 and LY294002 alone or in combination for 14 days. The cell numbers were determined by staining with Hoechst 33258.
Increased Antitumor Activity by Combining an ERRa Antagonist with BEZ235
There are several PI3K/mTOR inhibitors in clinical development for the treatment of a variety of cancers, although it is clear that their full potential is likely to be limited by dose-limiting toxicities (Bendell et al., 2015; Burris et al., 2010) . Indeed, in a pilot study in mice using BEZ235 (30-50 mg/kg/d, high dose), a dose that is used in most published studies, we observed profound toxicities consistent with those seen in ongoing clinical trials (Burris et al., 2010) . Considering these liabilities, it is clear that there is an unmet medical need for combination regimens that can increase the antitumor efficacy of PI3K/mTOR inhibitors while sparing other organs/systems. The results of the studies described thus far suggest that inhibition of ERRa function in tumors may result in a significant increase in tumor sensitivity to these targeted therapies. To test this hypothesis, the efficacy of a low dose of BEZ235 alone (10 mg/kg/d, low dose), or in combination with Cpd29, on the growth of MDA436 xenografts was assessed. The lower dose of BEZ235 used for these studies did not cause any noticeable treatment-related toxicities. As shown, tumor volume ( Figure 7A ) and final tumor weight (Figure 7B) in both the BEZ235 and Cpd29 treated mice were significantly reduced in comparison to those in the control (vehicle) group. The most important observation was that the combination of BEZ235 and Cpd29 was much more effective than either monotherapy alone. These data provide strong rationale for the development of ERRa antagonists for use in combination therapies for TNBC and possibly other cancers.
DISCUSSION
The observation that most oncogenes increase glucose uptake and/or utilization supports the strongly held hypothesis that increased reliance on glycolytic metabolism is an inherent property of transformed cells. It has been determined, however, that up to 90% of the ATP generated within some cancer cells is produced by mitochondria and that complete oxidation of glucose can occur in as low as 0.5% oxygen (Chandel et al., 1996; Rumsey et al., 1990; Zu and Guppy, 2004) . The results of the studies presented herein indicate that intact mitochondrial function, and the ability to oxidize lactate, confers upon breast cancer cells the ability to survive under glucose limiting conditions. Notably, inhibition of ERRa (using antagonists or siRNAs), or complex I (using metformin) have minimal effects on cell growth/viability in glucose replete conditions, but induce substantial apoptosis in cells when grown at concentrations of glucose that exist in tumors. It was further demonstrated that the ability to switch from glucose to lactate as a respiratory substrate has a significant impact on the efficacy of some drugs. Most significant was the observation that PI3K or dual PI3K/mTOR inhibitors are without effect in breast cancer cells when glucose is limiting and cells are forced to oxidize lactate. These findings are in line with those of others which have indicated that resistance to (1) inhibition of Kras pathway in pancreatic cancer (Viale et al., 2014) , (2) BRAF inhibitors in melanoma (Haq et al., 2013) , and (3) oxaliplatin and 5-fluorouracil in colon cancer (Vellinga et al., 2015) are associated with a shift to oxidative metabolism. Lactate has been an enigmatic molecule in cancer biology, and it remains unclear how it contributes to the pathobiology of tumors. Given that its production increases intratumoral acidification, it has been proposed that it is a liability to tumors, a conclusion that is supported by the observation that most tumors express carbonic anhydrase IX (Swietach et al., 2007) . However, the acidification in tumors is no different from that which occurs in exercising muscle where it has no deleterious effects, but rather may encourage a shift from glucose to fatty acid metabolism (Philp et al., 2005) . Indeed, our studies suggest that the ability to produce and maintain the local concentration of lactate may be beneficial to the viability of the tumor. This contention is supported by the observation that under conditions of glucose deprivation, lactate can be completely oxidized by cancer cells, entering the TCA cycle and sustaining ATP levels. Importantly, no evidence for lactate-supported gluconeogenesis was observed in our isotopomer analysis; furthermore, knock down of pyruvate carboxylase did not attenuate the protective effect of lactate. It is important to note that lactate supplementation did not protect against cell death in all cancer cells examined in this study. We have as yet been unable to define the specific pathways, proteins, or processes that confer upon cells the ability to utilize lactate as a sole carbon source in glucose deprived conditions. However, we have found that lactate utilization requires GSH and thus it may be differences in the ability to produce the reducing equivalents needed to accommodate the ROS production associated with increased oxidation that determines whether or not lactate can be utilized by cancer cells. Our studies have focused primarily on lactate as a fuel source in cancer cells, although the work of others has indicated that it may also play a role as a signaling molecule. Recent work has shown that lactate is a ligand for GPR81, a G protein-coupled receptor that is expressed in some cancer cell lines and in pancreatic tumors whose activation leads to increased expression of the monocarboxylate transporters and increased lactate uptake (Roland et al., 2014) . We did not find appreciable expression of this receptor in the cellular models that were used in our studies and thus believe that this aspect of lactate biology is distinct from that which we have described.
In addition to supporting lactate oxidation, mitochondrial activity contributes to cancer pathogenesis by supporting glutaminolysis, fatty acid oxidation, and by regulating autophagy (Guo and White, 2013; Wise et al., 2008) . Cumulatively, these findings reinforce the importance of the mitochondria as a therapeutic target in cancer. Indeed, metformin, a safe and well-tolerated medication and an inhibitor of mitochondrial complex I, inhibits tumor growth in animals and is currently being explored as a cancer therapeutic, albeit at doses higher than those used for the management of type II diabetes (Wheaton et al., 2014) . Our data suggest that small molecule antagonists of ERRa may be another useful way to inhibit mitochondrial function in cancer cells. This conclusion is supported by the observation that (1) ERRa expression and activity is elevated in tumors, (2) the phenotypes manifest in ERRa knockout in mice are subtle, and (3) the existing ERRa antagonists are well tolerated in animals. It has been suggested previously that ERRa may regulate the expression of genes involved in glycolysis, explaining some of the beneficial activity of ERRa antagonists (Charest-Marcotte et al., 2010) . However, this was not observed in the cellular models we studied and indeed we noticed a small, but robust, increase in glycolysis upon administration of ERRa antagonists, an effect that we have ascribed to a compensatory increase in glycolysis. This conclusion is in line with the findings of others, which revealed that cells can revert to glycolytic energy metabolism upon the inhibition of PGC1a expression in cellular models of melanoma and colon cancer (Lim et al., 2014; Vellinga et al., 2015) . Thus, we believe that ERRa antagonists, while influencing multiple aspects of tumor biology, can also function as cancer cell selective inhibitors of mitochondrial metabolism, but they may also have to be used in combination with other agents that target glycolysis.
One of the most remarkable findings in this study was that when utilizing lactate, some breast cancer cells were found to be completely insensitive to the actions of PI3K and dual PI3K/ mTOR inhibitors, suggesting that by relying more on oxidative, as opposed to glycolytic metabolism, cells can bypass the inhibitory activity of targeted therapies. It was of particular interest that we observed that cells expressing PIK3CA mutations were exquisitely sensitive to these inhibitors regardless of whether they were grown in glucose or lactate. However, in cells expressing PI3Kwt, sensitivity was only apparent in high glucose conditions. This finding may explain in part the heterogeneous response to this class of agents that has been observed in clinical trials. We conclude that (1) metabolic flexibility limits the effectiveness of interventions that target specific aspects of metabolism, (2) metabolic heterogeneity will likely impact response to drugs that inhibit oncogenes/signaling pathways that target glycolysis, and (3) the evaluation of drug efficacy in idealized metabolic conditions in vitro has significant limitations. In conclusion, the studies presented indicate that like in other metabolically active tissues, lactate is an important respiratory substrate, and the ability to use it efficiently confers a growth advantage upon tumors.
EXPERIMENTAL PROCEDURES
Detailed experimental procedures, cell lines, and reagents used in this study are provided in Supplemental Information.
Proliferation Assays MDA436 (9,000 cells/well) were seeded in 96-well plates containing regular RPMI (8% FBS and 2 mM glutamine) for 48 hr and subsequently replaced with glucose-free RPMI (10% dialyzed FBS and 2 mM glutamine) supplemented with 10 mM sodium lactate or MP (time zero). Cells were harvested 2, 4, 6, 8, or 10 days after treatment. Cell numbers were determined by staining with the DNA dye Hoechst 33258 (Sigma) and resulting fluorescence was read at excitation 346 nm and emission 460 nm using a Fusion microplate reader (PerkinElmer).
Xenograft Experiments
Animals were maintained in accordance with the NIH Guide for Care and Use of Laboratory Animals, and all procedures were approved by the Duke University Institutional Animal Care and Use Committees. MDA436 cells (2.5 3 10 6 ) in 50% Matrigel (BD Biosciences) were injected into the mammary fat pad of 8-week-old female NOD.SCID.gamma (NSG) mice. When tumors reached 150 mm 3 , mice were randomized and treated once daily by oral gavage with vehicle (10% NMP and 90% PEG300), BEZ235 (10 mg/kg/day), Cpd29 (30 mg/kg/day), or in combination. All drugs were solubilized in 1 volume of N-methylpyrrolidone (NMP) and 9 volumes of PEG300. Tumor size was measured with calipers three times a week, and tumor volume was calculated as (width 2 3 length)/2. Statistical comparison among groups was carried out using two-way ANOVA followed by a Bonferroni multiple comparison test.
U-
13
C Lactate and U-13 C Glutamine Isotopomer Analysis MDA436 (3.5 3 10 5 cells/well) or HCC1937 (3 3 10 5 cells/well) cells were seeded in 6-well plates containing regular RPMI for 48 hr and then replaced with glucose-free RPMI (10% dialyzed FBS and 2 mM glutamine) supplemented with 10 mM sodium lactate. After incubation at 37 C for 40 hr, cells were washed with PBS. Glucose-free RPMI (10% dialyzed FBS and 2 mM glutamine) containing 10 mM [U-
C] lactate or glucose and glutamine-free DMEM (10% dialyzed FBS) containing 10 mM sodium lactate and 2 mM [U-13 C] glutamine were then added. After 6 and 24 hr, the metabolites were extracted as described previously . 
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